TNF and neoplasm: Specifically, targeting CAFs increases bioavailability of chemotherapeutic agents including doxorubicin and gemcitabine, while enabling immunological surveillance and tumor destruction through a process that engages interferon-gamma (IFNγ) and tumor necrosis factor alpha (TNF-α) (Kraman et al., 2010; Olive et al., 2009).